ORTHOPEDIATRICS CORPKIDSEarnings & Financial Report
OrthoPediatrics is an American bio-science company engaged in designing, developing, manufacturing, and distributing orthopedic implants and instruments for pediatric issues. It is based in Warsaw, Indiana.
Revenue
$52.8M
Gross Profit
$40.8M
Operating Profit
$-5.7M
Net Profit
$-6.0M
Gross Margin
77.3%
Operating Margin
-10.7%
Net Margin
-11.4%
YoY Growth
33.5%
EPS
$-0.26
ORTHOPEDIATRICS CORP Q2 FY2024 Financial Summary
ORTHOPEDIATRICS CORP reported revenue of $52.8M (up 33.5% YoY) for Q2 FY2024, with a net profit of $-6.0M (down 108.9% YoY) (-11.4% margin). Cost of goods sold was $12.0M, operating expenses totaled $46.5M.
Key Financial Metrics
| Total Revenue | $52.8M |
|---|---|
| Net Profit | $-6.0M |
| Gross Margin | 77.3% |
| Operating Margin | -10.7% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
ORTHOPEDIATRICS CORP Q2 FY2024 revenue of $52.8M breaks down across 3 segments, led by Trauma And Deformity at $37.8M (71.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Trauma And Deformity | $37.8M | 71.5% |
| Spine | $13.7M | 25.9% |
| Sports Medicine And Other | $1.3M | 2.6% |
ORTHOPEDIATRICS CORP Revenue by Segment — Quarterly Trend
ORTHOPEDIATRICS CORP revenue by segment across the last 4 reported quarters, showing how each business line (such as Trauma And Deformity and Spine) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Trauma And Deformity | — | $44.1M | $41.7M | $37.9M |
| Spine | — | $16.3M | $18.5M | $13.7M |
ORTHOPEDIATRICS CORP Annual Revenue by Year
ORTHOPEDIATRICS CORP annual revenue history includes year-by-year totals (for example, 2025 revenue was $236.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $236.3M |
| 2024 | $204.7M |
| 2023 | $148.7M |
| 2022 | $122.3M |
ORTHOPEDIATRICS CORP Quarterly Revenue & Net Profit History
ORTHOPEDIATRICS CORP results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $61.6M | +17.0% | $-10.1M | -16.4% |
| Q3 FY2025 | $61.3M | +12.2% | $-11.8M | -19.2% |
| Q2 FY2025 | $61.1M | +15.7% | $-7.1M | -11.6% |
| Q1 FY2025 | $52.4M | +17.3% | $-10.7M | -20.3% |
| Q4 FY2024 | $52.7M | +40.0% | $-16.1M | -30.5% |
| Q3 FY2024 | $54.6M | +36.5% | $-7.9M | -14.5% |
| Q2 FY2024 | $52.8M | +33.5% | $-6.0M | -11.4% |
| Q1 FY2024 | $44.7M | +41.5% | $-7.8M | -17.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44.7M | $52.8M | $54.6M | $52.7M | $52.4M | $61.1M | $61.3M | $61.6M |
| YoY Growth | 41.5% | 33.5% | 36.5% | 40.0% | 17.3% | 15.7% | 12.2% | 17.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $437.2M | $430.8M | $489.3M | $473.2M | $470.3M | $503.6M | $493.5M | $508.6M |
| Liabilities | $66.6M | $59.5M | $118.4M | $118.6M | $123.1M | $148.1M | $144.2M | $162.0M |
| Equity | $370.6M | $371.3M | $370.9M | $354.6M | $347.1M | $355.5M | $349.3M | $346.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-6.7M | $-6.1M | $-10.3M | $-4.0M | $-4.2M | $-10.5M | $-581000 | $10.3M |